• Home
  • Journals
  • Focus
  • Conferences
  • Researchers
  • Sign in

Outline

  • Abstract
  • Keywords

Figures(5)

标签(1)

Table 1

其他(2)

PDF
Document

Frontiers of Medicine

    • PDF
    • collect

    Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia

    . Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.. Pôle de Recherches Sino-Français en Science du Vivant et Génomique, Laboratory of Molecular Pathology, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

    Received：2020-11-27 Accepted： 2020-12-24 Available online：2020-12-24
    Show More
    10.1007/s11684-020-0821-6
    Cite this article
    Jianfeng Li, Yuting Dai, Liang Wu, Ming Zhang, Wen Ouyang, Jinyan Huang, Saijuan Chen.Emerging molecular subtypes and therapeutic targets in B-cell precursor acute lymphoblastic leukemia[J].Frontiers of Medicine:0-

    Abstract

    B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is characterized by genetic alterations with high heterogeneity. Precise subtypes with distinct genomic and/or gene expression patterns have been recently revealed using high-throughput sequencing technology. Most of these profiles are associated with recurrent non-overlapping rearrangements or hotspot point mutations that are analogous to the established subtypes, such as rearrangements, rearrangements, rearrangements, rearrangements, / and/or rearrangements, like gene expression, PAX5alt (diverse alterations, including rearrangements, intragenic amplifications, or mutations), and hotspot mutations PAX5 (p.Pro80Arg) with biallelic alterations, IKZF1 (p.Asn159Tyr), and ZEB2 (p.His1038Arg). These molecular subtypes could be classified by gene expression patterns with RNA-seq technology. Refined molecular classification greatly improved the treatment strategy. Multiagent therapy regimens, including target inhibitors (e.g., imatinib), immunomodulators, monoclonal antibodies, and chimeric antigen receptor T-cell (CAR-T) therapy, are transforming the clinical practice from chemotherapy drugs to personalized medicine in the field of risk-directed disease management. We provide an update on our knowledge of emerging molecular subtypes and therapeutic targets in BCP-ALL.

    Keywords

    BCP-ALL ; subtypes ; translocation ; aneuploidy ; sequence mutations
    Previous article in issue
    article in issue Next
    登录后，您可以进行评论。请先登录

    评论

    评论

    • 所有评论
     咋就跳到顶部了
    2019-04-23 11:24:14
    回复 (0)
    inspur  手机账号
    2019-05-10 11:30:17
    回复 (0)

    Read

    30

    Download

    0

    Related Research

    Current Issue
      Current Issue
        Follow us
        Copyright © 2015 China Engineering Science Press.
        京ICP备11030251号
        Follow us
        Copyright © 2015 China Engineering Science Press.
        京ICP备11030251号